Thromb Haemost 1999; 82(06): 1578-1582
DOI: 10.1055/s-0037-1614881
Rapid Communication
Schattauer GmbH

Increased Levels of Tissue Factor mRNA in Mononuclear Blood Cells of Patients with Primary Antiphospholipid Syndrome

Pablo M. Dobado-Berrios
1   From the Departments of Research, Reina Sofia University Hospital, Cordoba, Spain
,
Chari López-Pedrera
1   From the Departments of Research, Reina Sofia University Hospital, Cordoba, Spain
,
Francisco Velasco
2   Haematology and Haemotherapy, Reina Sofia University Hospital, Cordoba, Spain
,
María A. Aguirre
3   Rheumatology, Reina Sofia University Hospital, Cordoba, Spain
,
Antonio Torres
2   Haematology and Haemotherapy, Reina Sofia University Hospital, Cordoba, Spain
,
María J. Cuadrado
3   Rheumatology, Reina Sofia University Hospital, Cordoba, Spain
› Author Affiliations

This work was supported by grant No. 97/0408 from the Fondo de Investigación Sanitaria (FIS) of Spain. We thank Dr. Gabriel Dorado, Fernando Luque and José M. Lozano for expert technical assistance and Dr. Munther A. Khamashta for critically reading the manuscript
Further Information

Publication History

Received 02 June 1999

Accepted after revision 31 August 1999

Publication Date:
10 December 2017 (online)

Preview

Summary

Antiphospholipid antibodies (aPL) may stimulate tissue factor (TF) expression in cultured endothelial cells and monocytes, but there are discrepancies as to the expression of TF in the patients with antiphospholipid syndrome (APS). By using reverse transcription and polymerase chain reaction amplification, we have analysed TF mRNA accumulation in freshly isolated mononuclear blood cells (MBC) of 14 patients with primary APS (PAPS) and six normal controls. TF mRNA accumulation was low or absent in uncultured MBC from all normal controls, but was elevated in uncultured MBC from nine of the patients as well as in normal MBC incubated with 100 ng/ml lipopolysaccharide (LPS). Mean levels of TF mRNA, as measured by densitometry, were higher in MBC from patients (N = 14) than in those from controls (N = 6, P = 0.009), and in MBC from patients with a history of thrombosis (N = 9) than in those from patients without thrombosis (N = 5, P = 0.02). Uncultured MBC of patients with thrombosis accumulated TF mRNA at similar levels to LPS-treated normal MBC. Increased levels of TF mRNA were found in eight of ten patients with conventional aPL (ie, anti-cardiolipin antibodies [aCL] and/or lupus anticoagulant [LA]) and littleif any accumulation of TF mRNA was observed in three of four patients without aPL at the time of study. These data strongly suggest that circulating monocytes of many patients with PAPS are subjected to an up-regulated TF expression that may well explain their prothrombotic state. Although the presence or absence of TF mRNA in MBC was associated with, respectively, the presence or absence of conventional aPL in 11 of the 14 patients studied, our study cannot exclude the involvement of factors other than aCL or LA in inducing TF expression.